Search Results - "Tursi, Antonio"

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Authors: Tursi, Antonio Mocci, Giammarco Costa, Francesco et al.

Source: Intestinal Research. Apr2026, Vol. 24 Issue 2, p341-351. 11p.

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Authors: Mocci, Giammarco Tursi, Antonio Scaldaferri, Franco et al.

Source: Journal of Clinical Medicine. Nov2025, Vol. 14 Issue 21, p7801. 19p.

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Authors: Mocci, Giammarco Tursi, Antonio Scaldaferri, Franco et al.

Source: Journal of Clinical Medicine. Dec2024, Vol. 13 Issue 23, p7192. 15p.

Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study.

Authors: Tursi, Antonio Piovani, Daniele Brandimarte, Giovanni et al.

Source: Intestinal Research. Jan2025, Vol. 23 Issue 1, p96-106. 11p.

Evaluation of the Effect of a Cranberry Formulation in Reducing the Inflammatory State and Improving the Management of Symptoms in Patients with Symptomatic Uncomplicated Diverticular Disease: A Prospective, Open-Label, Single-Arm, Multi-Center, Pilot Study

Authors: Tursi, Antonio Rodinò, Stefano Sebkova, Ladislava et al.

Source: Pharmaceutics. Jan2026, Vol. 18 Issue 1, p42. 14p.

Gut Microbiota May Predict the Short-Term Recurrence of Symptomatic Uncomplicated Diverticular Disease.

Authors: Tursi, Antonio Procaccianti, Giorgia Turroni, Silvia et al.

Source: Journal of Gastrointestinal & Liver Diseases. May2026, Vol. 35 Issue 1, p38-42. 5p.

The role of gut microbiota in the pathogenesis of diverticular disease: where are we now?

Authors: Tursi, Antonio Papa, Alfredo

Source: Genome Medicine. 12/30/2024, Vol. 16 Issue 1, p1-4. 4p.

El De moneta de Nicolás de Oresme en la tradición de tratados publicistas y de la recepción de Política en el siglo XIV. (Spanish)

Authors: GIGLIO, JULIÁN¹, thebargeman@gmail.com

Source: Scripta Mediaevalia; 2023, Vol. 16 Issue 2, p125-167, 43p

Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis.

Authors: Tursi, Antonio Pellegrino, Raffaele Mocci, Giammarco et al.

Source: Journal of Clinical Medicine. Nov2025, Vol. 14 Issue 21, p7476. 19p.

Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus -Based Nutraceutical Add-on Multi-Compound: The "HERICIUM-UC" Two-Arm Multicentre Retrospective Study.

Authors: Tursi, Antonio D'Avino, Alessandro Brandimarte, Giovanni et al.

Source: Pharmaceutics. Sep2024, Vol. 16 Issue 9, p1133. 13p.

Gut Microbiota Perturbation Are Linked to Endoscopic Severity of Diverticular Disease.

Authors: Tursi, Antonio Procaccianti, Giorgia Turroni, Silvia et al.

Source: Journal of Gastrointestinal & Liver Diseases. Sep2025, Vol. 34 Issue 3, p317-322. 6p.

Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.

Authors: Mocci, Giammarco Tursi, Antonio Onidi, Francesca Maria et al.

Source: Journal of Clinical Medicine. Mar2024, Vol. 13 Issue 5, p1519. 16p.

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life.

Authors: Mocci, Giammarco Tursi, Antonio

Source: Alimentary Pharmacology & Therapeutics. Nov2024, Vol. 60 Issue 10, p1459-1460. 2p.

Microbiota Composition in Diverticular Disease: Implications for Therapy.

Authors: Tursi, Antonio Papa, Valerio Lopetuso, Loris Riccardo et al.

Source: International Journal of Molecular Sciences. Dec2022, Vol. 23 Issue 23, p14799. 12p.

Removal of Non-Steroidal Anti-Inflammatory Drugs from Drinking Water Sources by GO-SWCNT Buckypapers.

Authors: Baratta, Mariafrancesca Tursi, Antonio Curcio, Manuela et al.

Source: Molecules. Nov2022, Vol. 27 Issue 22, p7674. 14p.

Improvement in Chronic Atrophic Gastritis After Treatment with Zinc L-Carnosine.

Authors: De Bastiani, Rudi Fassan, Matteo Businello, Gianluca et al.

Source: American Journal of Case Reports. 11/20/2025, Vol. 26, p1-7. 7p.

Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease.

Authors: Tursi, Antonio Mocci, Giammarco Picchio, Marcello et al.

Source: Alimentary Pharmacology & Therapeutics. Apr2021, Vol. 53 Issue 7, p859-860. 2p. 1 Chart.

MWCNTs Decorated with TiO 2 as Highly Performing Filler in the Preparation of Nanocomposite Membranes for Scalable Photocatalytic Degradation of Bisphenol A in Water.

Authors: Tursi, Antonio Beneduci, Amerigo Nicotera, Isabella et al.

Source: Nanomaterials (2079-4991). Aug2023, Vol. 13 Issue 16, p2325. 19p.

Subjects: Irradiation, Bisphenol A, Polyethersulfone, Photodegradation, Hybrid materials, Titanium dioxide, Multiwalled carbon nanotubes, Chemical stability

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.

Authors: Tursi, Antonio Mocci, Giammarco Cuomo, Antonio et al.

Source: Journal of Gastrointestinal & Liver Diseases. Dec2022, Vol. 31 Issue 4, p411-416. 6p.

GO-SWCNT Buckypapers as an Enhanced Technology for Water Decontamination from Lead.

Authors: Baratta, Mariafrancesca Tursi, Antonio Curcio, Manuela et al.

Source: Molecules. Jul2022, Vol. 27 Issue 13, p4044-N.PAG. 12p.